Navigation Links
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Date:12/13/2007

Oral Presentation of the US Oncology Adjuvant Trial 9735 at 2007 San Antonio Breast Cancer Symposium Showed Taxotere(R) and Cyclophosphamide

Improved Overall Survival Versus An Anthracycline Combination

SAN ANTONIO, Dec. 13 /PRNewswire-FirstCall/ -- Results presented at the 30th annual San Antonio Breast Cancer Symposium (SABCS) showed that for women with early stage breast cancer who have had surgery, treatment with the investigational chemotherapy combination of Taxotere(R) (docetaxel) Injection Concentrate and cyclophosphamide significantly improved overall survival compared to standard chemotherapy. The presentation reports results with a median follow-up of seven years and has been updated since the last report was published with 5.5 years median follow-up [Jones S et al. J Clin Oncol, 2006, 24:5381-7]. This latest report has also been updated from the abstract submitted to SABCS 2007.

In the updated analysis, overall survival at seven years was statistically higher among women treated with Taxotere(R) and cyclophosphamide (TC) versus those treated with doxorubicin and cyclophosphamide (AC): 87% versus 82% (HR: 0.69, [95% CI, 0.50, 0.97]). The 31% reduction in the risk of death was statistically significant (p=0.032). At seven years, the disease-free survival (DFS) was also statistically greater among women treated with TC than those treated with AC: 81% versus 75% (HR: 0.74, [95% CI, 0.56, 0.98]). The 26% reduction in the risk of cancer recurrence among women treated with TC was statistically significant (p=0.033). The disease-free survival benefit seen in the elderly patients (aged 65 years or older; 31% risk reduction of recurrence) is consistent with that in the overall patient population.

Principal study investigator Dr. Stephen Jones, medical director and co-chair, breast cancer research committee of US Oncology, helped develop the regimen combining the anthracycline doxorubicin with cyclophosphamide, which became a
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
2. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
3. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
4. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
5. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
6. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
9. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
10. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
11. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc., an early stage biotech startup based on perinatal ... the Musculoskeletal Transplant Foundation of Edison NJ ... round of development of the proprietary AmnioCept™ product line ... AmnioChor,s technology allows cryopreservation of the amniotic membrane of ... those tissues. Amnion is a well-established source of multipotent ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for the ... system received a score of 0 (range -10 to +10) for its impact on ... Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes to ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... meeting with U.S. Health and Human Services ... healthcare organizations pledged to support health information technology by ... information technology products used by their health plans. ... to support a national initiative aimed at improving healthcare ...
... for today's success are flexibility, adaptability, creativity, and technology. ... compete in the global marketplace. This transcends all industries ... is a shortage of highly skilled, technical people in ... qualified, highly skilled, technical people here, but many companies ...
... Milwaukee, Wis. - Rick Davidson jokes about his ... in your title, and your company operates in 72 countries, ... jest. , ,Not that the good-humored Davidson, senior vice president ... to exaggeration. The Milwaukee-based employment services firm has 400,000 customers ...
Cached Biology Technology:Wisconsin firms pledge to support healthcare IT standards 2Getting beyond the vortex of corporate mediocrity 2Getting beyond the vortex of corporate mediocrity 3Getting beyond the vortex of corporate mediocrity 4CIO Leadership Series: Rick Davidson, Manpower 2CIO Leadership Series: Rick Davidson, Manpower 3CIO Leadership Series: Rick Davidson, Manpower 4CIO Leadership Series: Rick Davidson, Manpower 5
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... public attention gravitates towards conflict and natural disaster, many ... with some of the same nutrition problems as those ... Rainer Gross, PhD, UNICEF's chief of nutrition, and Patrick ... School of Nutrition Science and Policy at Tufts University, ...
... been used topically in many skin creams and cosmetics ... skin. Now, new research just published in the Journal ... cocoa and how it might actually benefit skin from ... in cocoa may actually help improve the appearance of ...
... at Rice University's Laboratory for Nanophotonics (LANP) have ... family ultrasmall, light-focusing particles. A cousin of the ... whose striking optical properties can be harnessed for ... , Nanoeggs are described in the July 18 ...
Cached Biology News:Five surprising facts about starvation that could change the international agenda 2Five surprising facts about starvation that could change the international agenda 3New study reveals components of cocoa may enhance the appearance of the skin 2Rice scientists unveil 'nanoegg' 2
Direct ELISA Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
...
Fluorescence Preserving Media, 100 mL...
Biology Products: